For research use only. Not for use in humans.

Cadonilimab (Anti-PD-1 & CTLA-4)

Synonyms: AK104 Cat.No.A4002

Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.

Cadonilimab (Anti-PD-1 & CTLA-4)

Quality Control

Specificity

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-L1	PD-1/PD-L1	Others
GS-4224	0	++++			++++
INCB086550	1	++			++
BMS-1001	0	+			+
BMS-1166	7	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	13	++
BMS202	25	+
CA-170 (AUPM-170)	0			✔
SR 0987	1		✔			IL17,RORγt
Spartalizumab (anti-PD-1)	3		✔
Camrelizumab (anti-PD-1)	2		✔
AUNP-12	3			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2394841-59-7
Source	CHO
Storage (From the date of receipt)	-80℃(avoid freeze-thaw cycles)

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.